Browse by author
Lookup NU author(s): Dr Deborah Stocken
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Background: The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone. Synchronous chemotherapy regimens have yielded encouraging results in other primary sites. Patients and methods: Patients with T2-T4a NO/NX MO bladder cancer were entered into this single centre phase I-II study. Patients received radiotherapy to 55 Gy in 20 fractions over four weeks. Concurrent chemotherapy was given with Mitomycin C 12 mg/m2 day 1 and 5-fluorouracil 500 mg/m2/ 24 hours weeks one and four of radiotherapy for five or seven days on each occasion. Results: Thirty-one patients entered the trial from March 1998 to December 1999 (22: 5-day; 9: 7-day schedule). Median age was 68 (range 58-79) years, 23 males and 8 females; T2: 9 (29%); T3a: 4 (12%); T3b: 9 (29%); T4: 9 (29%); TCC grade 2: 8 (26%) and grade 3: 23 (74%); 14 of 31 had hydronephrosis. Ten of thirty-one had a GFR <50 ml/min. Toxicity was mild to moderate with the five-day schedule. More severe toxicity was seen with the seven-day schedule: five of nine patients failed to complete planned therapy. Pathological complete response rate at three months was 74% (5-day regimen) and 50% (7-day regimen). Overall 12-month survival was 65%. Conclusion: Chemoradiotherapy with the five-day schedule is feasible with acceptable toxicity in poor prognosis patients. A randomised trial is being launched.
Author(s): Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DMA, James ND
Publication type: Article
Publication status: Published
Journal: Annals of Oncology
Year: 2001
Volume: 12
Issue: 7
Pages: 929-935
Print publication date: 01/01/2001
ISSN (print): 0923-7534
ISSN (electronic): 1569-8041
Publisher: Oxford University Press
URL: http://dx.doi.org/10.1023/A:1011133820532
DOI: 10.1023/A:1011133820532
Altmetrics provided by Altmetric
